Aurinia Reports Presentation Of Two Studies At The Annual Congress Of Clinical Rheumatology
Aurinia Reports Presentation Of Two Studies At The Annual Congress Of Clinical Rheumatology
Aurinia在臨床風溼病學年度大會上報告了兩項研究的介紹
The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program.
如AURORA臨床計劃所示，這些數據強化了先前關於第二代鈣調神經素抑制劑（CNI）LUPKYNIS（voclosporin）與MMF和類固醇聯合治療活動性狼瘡腎炎（LN）成年患者的安全性和有效性的發現。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。